Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ATF4 | P18848 | 3/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21819289 | 0.92 | SLC2A1 (0.46) | SMN1; SMN2ATF4HRH4PKMNPC1 | |
| SCHEMBL21882079 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2PKMCHRM3ALDH1A1LMNA | |
| SCHEMBL21882371 | 0.79 | ATF4 (0.53) | ATF4HRH4 | |
| Trifluoroacetic Acid SCHEMBL21819605 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2PKMCHRM3ALDH1A1LMNA | |
| SCHEMBL21882370 | 0.76 | L3MBTL1 (0.55) | ATF4HRH4NPC1RAB9A | |
| SCHEMBL21819310 | 0.75 | KMT2A (0.54) | SMN1; SMN2ATF4HRH4LMNA | |
| Hydrochloric Acid SCHEMBL6578952 | 0.74 | GAA (0.47) | SMN1; SMN2PKM | |
| SCHEMBL1721295 | 0.73 | CYP2D6 (0.67) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27606796 | 0.73 | HTT (0.47) | SMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL21819270 | 0.73 | ATF4 (0.50) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | SMN1; SMN2 3465/4885ATF4 1/4885HRH4 1989/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | SMN1; SMN2 3465/4885ATF4 1/4885HRH4 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.